CN118956732B - Duck eye cornea epithelial cell suspension cell strain, construction method and application thereof - Google Patents
Duck eye cornea epithelial cell suspension cell strain, construction method and application thereofInfo
- Publication number
- CN118956732B CN118956732B CN202411276253.1A CN202411276253A CN118956732B CN 118956732 B CN118956732 B CN 118956732B CN 202411276253 A CN202411276253 A CN 202411276253A CN 118956732 B CN118956732 B CN 118956732B
- Authority
- CN
- China
- Prior art keywords
- duck
- cells
- culture
- virus
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
- C12N2509/10—Mechanical dissociation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10051—Methods of production or purification of viral material
- C12N2750/10052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
- C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24151—Methods of production or purification of viral material
- C12N2770/24152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
Abstract
本发明属于生物技术领域，具体涉及一种鸭眼角膜上皮细胞悬浮细胞株及其构建方法与应用。本发明首次在鸭上分离获得成眼角膜上皮细胞，并成功悬浮驯化，名称为麻鸭眼角膜上皮悬浮细胞DCE‑S，于2024年6月28日保藏于位于中国.武汉.武汉大学的中国典型培养物保藏中心，保藏编号为CCTCC NO：C2024189。该细胞株易于培养，生长速度较快，能够稳定传代，细胞密度高，可达6～8×106cells/mL，呈单个分散生长，形态饱满，大小均一，细胞活率高、适用于生物反应器无血清悬浮培养的细胞株。该细胞株可用于培养、分离、检测禽类病毒，制备禽类疫苗，筛选用于预防或治疗禽类病毒感染所致的疾病的药物。The present invention belongs to the field of biotechnology, and specifically relates to a duck corneal epithelial cell suspension cell line, and its construction method and application. The present invention isolated and obtained adult corneal epithelial cells from ducks for the first time, and successfully suspended and domesticated them. The name is duck corneal epithelial suspension cells DCE-S, which were deposited in the China Center for Type Culture Collection at Wuhan University, Wuhan, China on June 28, 2024, with the deposit number CCTCC NO: C2024189. The cell line is easy to culture, grows rapidly, can be stably passaged, has a high cell density of 6 to 8×10 6 cells/mL, grows in a single dispersed manner, has a plump morphology, is uniform in size, has a high cell viability, and is suitable for serum-free suspension culture in bioreactors. The cell line can be used to culture, isolate, and detect avian viruses, prepare avian vaccines, and screen drugs for the prevention or treatment of diseases caused by avian viral infections.
Description
Technical Field
The invention belongs to the technical field of biology, and particularly relates to a duck eye cornea epithelial cell suspension cell strain, a construction method and application thereof.
Background
The production and consumption of meat ducks are large, 30 or more hundred million meat ducks are produced annually, the annual output is over 1000 hundred million yuan, the frequency of fowl diseases is increased along with the increase of the feeding amount, and the diseases are the most serious diseases endangering the aquatic fowl breeding industry, such as avian influenza (subtype H5, H7, H9, and the like), duck plague, duck viral hepatitis, young duck gosling plague, muscovy duck parvovirus disease, duck coronavirus enteritis, duck pox, muscovy duck reovirus disease, novel viral infectious diseases such as duck reovirus disease, duck paramyxovirus disease, duck torus, duck tembusu virus disease, and the like, and the development of the fowl breeding industry is severely restricted.
Vaccine immunization is the most effective means for preventing animal epidemic diseases, and domestic poultry vaccine production mainly depends on a chick embryo culture process, a poultry primary cell culture process and a passage cell culture process. The chick embryo culture process has the advantages of long culture period, complicated operation steps, high production cost, unstable chick embryo quality and potential exogenous virus pollution during large-scale production, difficult innocent treatment of waste embryo after harvesting, and virus diffusion risk and environmental pollution. The fowl primary cell culture process needs to prepare fresh primary cells each time, and virus vaccine can be produced only through an adherence culture process, on one hand, serum maintenance culture is needed, the cost is high, on the other hand, the scale of amplification is limited, and the virus yield is reduced due to the limitation of the surface area of a substrate, so that pollution and batch-to-batch quality inconsistency are easy to occur. The existing cell-derived vaccine mainly adopts heterologous cells (such as canine kidney cells (MDCK suspension cells) to culture avian influenza virus) as a culture medium for virus production, and the vaccine immune effect is slightly poorer than that of chicken embryo culture.
The research and development of poultry cells in China are less, and a commercial duck-origin cell line is not available. In order to better and more effectively separate, proliferate and produce avian viruses, develop a special vaccine for waterfowl and prevent disease outbreaks, develop a duck-origin cell suspension cell strain suitable for industrialized mass production, and have great significance.
The application number 202111338851.3 of goose retina epithelial cell line, a construction method and application thereof mainly obtains 1 strain of low-serum adherence culture type goose retina epithelial cell line which is not a duck source cell line and can not be subjected to serum-free suspension culture.
The application number 202210113778.8 of the pig retina epithelial cell line, the construction method and the application thereof mainly obtains 1 pig retina epithelial cell line which is not a duck source cell line and can not be subjected to serum-free suspension culture.
Disclosure of Invention
The object of the first aspect of the invention is to provide a cell line.
The object of the second aspect of the present invention is to provide a method for constructing the cell line of the first aspect of the present invention.
A third aspect of the invention is directed to a use.
The fourth aspect of the present invention is directed to a method for culturing viruses.
The object of the fifth aspect of the present invention is to provide a method for viral vaccine.
The sixth aspect of the present invention is directed to a viral vaccine.
In order to achieve the above purpose of the present invention, the present invention adopts the following technical scheme:
In a first aspect of the invention, a duck eye cornea epithelial cell line, named sheldrake eye cornea epithelial suspension cell DCE-S (sheldock), was deposited at 28 days of 6 months of 2024 at China center for type culture Collection, university of Wuhan, china, with a deposit number of CCTCC NO: C2024189.
In a second aspect of the present invention, there is provided a method for constructing a duck eye cornea epithelial cell line according to the first aspect of the present invention, comprising the steps of:
1) Separating eyeballs of duck embryos, separating corneas of the eyeballs, and shearing into tissue blocks;
2) Adding a first culture medium, uniformly mixing, culturing, and carrying out passage for 5-15 generations;
3) Culturing by using a second culture medium, and carrying out passage for 3-5 generations;
4) Culturing by using a third culture medium, and carrying out passage for 3-5 generations;
5) Culturing by using a fourth culture medium, carrying out passage for 3-5 generations,
6) And culturing by using a serum-free suspension culture medium, and carrying out passage for 20-30 generations to obtain the strain.
Preferably, the first culture medium comprises 8-10 v/v% fetal bovine serum and a basal culture medium.
Preferably, the second culture medium comprises 6-8 v/v% fetal bovine serum and a basal culture medium.
Preferably, the third culture medium comprises 4-6 v/v% fetal bovine serum and a basal culture medium.
Preferably, the fourth culture medium comprises 2-3 v/v% fetal bovine serum and a basal culture medium.
Preferably, the basal medium comprises at least one of MEM medium, DMEM/F12 medium.
In some embodiments of the invention, the construction method comprises 1) taking 3 duck embryos of 7-11 days old, separating eyeballs by ophthalmic scissors, placing the duck embryos into a clean sterile plate, washing 3 times by precooled D-Hank's liquid, separating the corneas of eyes, shearing, adding a small amount of MEM of 8-10 v/v% fetal bovine serum, blowing broken tissue blocks, transferring into a culture bottle for culture under the culture condition of 37 ℃ and 5% CO 2 culture box, 2) after cell separation culture, gently shaking the cell bottle, discarding the supernatant, only leaving attached cells, supplementing MEM of fresh 8-10 v/v% fetal bovine serum, continuously culturing, inoculating 0.25wt% EDTA-pancreatin into holes of 96 hole plates according to average density of 0.5 cells/holes, obtaining single cell lines of the cornea after the cells in the single cell holes grow into colonies, and culturing under the condition of 578% CO 5-containing 10% fetal serum continuously, and culturing the duck embryos under the culture condition of 2 ℃ and 3% CO. Culturing in MEM medium containing 4-6 v/v% of fetal bovine serum after 3-5 passages, culturing in MEM medium containing 2-3 v/v% of fetal bovine serum after 3-5 passages, obtaining low-serum adherence culture type duck eye cornea epithelial cells after 3-5 passages, 4) culturing the low-serum adherence culture type duck eye cornea epithelial cells into a monolayer, digesting with 0.25wt% of EDTA-pancreatin, collecting cell suspension, centrifuging at 800-1000 rpm for 6min, discarding supernatant, leaving cell sediment, re-suspending the cell sediment with serum-free suspension medium, adjusting the cell density to 1.0X10 6 cells/mL, culturing in a shaking table under the culture conditions of 37 ℃ and 5% CO 2 and 100-130 r/min. Cell morphology was observed by sampling every 24 hours and counted. After culturing for 2-3 days, centrifuging, replacing liquid and passaging until the cell number of each cell is more than or equal to 6.0X10 6 cells/mL. And (3) stably and continuously culturing the cells for more than 30 generations to obtain serum-free total suspension culture type duck eye cornea epithelial cells, namely duck eye cornea epithelial cell suspension cell strains.
Preferably, the size of the tissue fragments in step 1) is 1-2 cm 3/pieces.
Preferably, the culture conditions are 31-39 ℃, 4-6% CO 2, and further 33-37 ℃ and 5% CO 2.
In a third aspect, the present invention provides the use of the duck eye cornea epithelial cell line of the first aspect of the invention in any one of 1) to 8):
1) Culturing the virus;
2) Preparing a product for culturing viruses;
3) Isolating the virus;
4) Preparing a virus-isolated product;
5) Detecting the virus at a non-diagnostic treatment destination;
6) Preparing a product for detecting viruses;
7) Preparing a virus vaccine;
8) Screening medicines;
the medicine is used for preventing or treating diseases caused by virus infection.
Preferably, the virus comprises at least one of an avian influenza virus, a duck circovirus, and a duck tembusu virus.
Preferably, the avian influenza virus comprises an H9 subtype avian influenza virus.
In a fourth aspect of the invention, there is provided a method of culturing a virus by inoculating the virus into the duck eye corneal epithelial cell line of the first aspect of the invention and culturing.
Preferably, the virus comprises at least one of an avian influenza virus, a duck circovirus, and a duck tembusu virus.
Preferably, the avian influenza virus comprises an H9 subtype avian influenza virus.
Preferably, the culture conditions are 31-39 ℃, 4-6% CO 2, and further 33-37 ℃ and 5% CO 2.
In a fifth aspect of the invention, there is provided a method of preparing a viral vaccine by inoculating a virus into the duck eye cornea epithelial cell line of the first aspect of the invention, culturing, and inactivating to obtain a viral vaccine.
Preferably, the virus comprises at least one of an avian influenza virus, a duck circovirus, and a duck tembusu virus.
Preferably, the avian influenza virus comprises an H9 subtype avian influenza virus.
Preferably, the culture conditions are 31-39 ℃, 4-6% CO 2, and further 33-37 ℃ and 5% CO 2.
In a sixth aspect of the invention there is provided a viral vaccine prepared by the method of the fifth aspect of the invention.
The beneficial effects of the invention are as follows:
The invention provides a duck eye cornea epithelial cell line, namely a shepherd' S eye cornea epithelial suspension cell DCE-S, which is preserved in China center for type culture collection, with the preservation number of CCTCCNO: C2024189, at the month of 2024, 6 and 28 days, through a great deal of creative labor of the inventor, firstly, the duck eye cornea epithelial cells are separated from ducks, and are successfully suspended and domesticated. The cell strain is easy to culture, has a high growth speed, can be stably passaged, has a high cell density which can reach 6-8 multiplied by 10 6 cells/mL, is single and dispersive to grow, has full shape and uniform size, has a high cell activity rate, and is suitable for serum-free suspension culture of a bioreactor. The cell strain can be used for culturing, separating and detecting avian viruses, preparing avian vaccines and screening medicines for preventing or treating diseases caused by avian virus infection. The cell strain provides an important culture medium for large-scale suspension culture, cost reduction and synergy of poultry vaccines.
Drawings
The invention is further described with reference to the accompanying drawings and examples, in which:
FIG. 1 shows the results of low serum wall-mounted cultured duck eye corneal epithelial cells of example 1, wherein the left side is the result after 24 hours of culture, and the right side is the result after 48 hours of culture.
FIG. 2 shows the results of growth state of the DCE-S generation 25 of the sheldrake eye corneal epithelial suspension cells.
FIG. 3 shows stable passaging of different generations of sheldrake eye corneal epithelium suspension cells DCE-S (F9-F30).
FIG. 4 shows cytopathic results of the DCE-S inoculation of the sheldrake eye corneal epithelial suspension cells with H9 subtype avian influenza virus for 72H.
FIG. 5 shows cytopathic results of duck eye corneal epithelial suspension cells DCE-S inoculated with duck circovirus virus for 60 h.
FIG. 6 shows cytopathic results of duck eye corneal epithelial suspension cells DCE-S inoculated with duck Tembusu virus for 50 h.
Detailed Description
The conception and the technical effects produced by the present invention will be clearly and completely described in conjunction with the embodiments below to fully understand the objects, features and effects of the present invention. It is apparent that the described embodiments are only some embodiments of the present invention, but not all embodiments, and that other embodiments obtained by those skilled in the art without inventive effort are within the scope of the present invention based on the embodiments of the present invention.
EXAMPLE 1 construction of Duck eye corneal epithelial cell suspension cell lines
1. Quick separation and culture of primary duck eye cornea epithelial cells
(1) Taking duck embryo hatched for 10 days old, and drawing air chamber boundary and fetal position after checking;
(2) Sterilizing embryo eggs with 75% alcohol, tapping and crushing the egg shells of the air chamber parts with sterilized forceps in a sterile operation table, removing the shell membranes of the air chamber parts with another sterile forceps, taking out embryo bodies with the other sterile forceps, and placing the embryo bodies in a sterile plate;
(3) Separating eyeball with ophthalmic scissors, placing into a clean sterile plate, washing 3 times with precooled D-Hank's liquid, separating cornea, shearing, adding a small amount of MEM (MEM) of 10v/v% fetal bovine serum, blowing broken tissue blocks, transferring into a culture bottle for culture under the culture condition of 37 ℃ and 5% CO 2 incubator;
(4) After 24 hours of cell separation and culture, gently shaking the cell bottle, discarding the supernatant, leaving only adherent cells, supplementing MEM with fresh 10% fetal bovine serum, and continuously culturing;
(5) After the cells grow into a monolayer, digestion treatment is carried out on the single cells by 0.25wt% of EDTA-pancreatin, then the single cells are inoculated into a 96-well plate according to the average density of 0.5 cells/well, the wells inoculated with the single cells are marked, and after the cells in the single cell wells grow into clone clusters, the duck eye cornea epithelial single cell strain can be obtained.
(6) Continuously passaging the duck eye cornea epithelial single cell strain to 10 generations to obtain an adherence culture type duck eye cornea epithelial cell with uniform morphology.
2. Construction of duck eye cornea epithelial cell suspension cell strain
(1) Obtaining low serum adherence culture type duck eye cornea epithelial cells, wherein the duck eye cornea epithelial cells in the step (6) of the step 1 grow into a single layer, the single layer is digested by 0.25wt% EDTA-pancreatin, and the single layer is cultured by adopting MEM culture medium containing 8v/v% fetal bovine serum, wherein the culture condition is 37 ℃ and a 5% CO 2 incubator. Culturing in MEM medium containing 6v/v% of fetal bovine serum after 5 continuous culture, culturing in MEM medium containing 3v/v% of fetal bovine serum after 5 continuous culture, and obtaining low-serum adherence culture type duck eye cornea epithelial cells after 5 continuous culture. The results are shown in FIG. 1.
(2) Obtaining duck eye cornea epithelial cell suspension cell strain, namely growing duck eye cornea epithelial cells into a single layer by low serum adherence culture, digesting by 0.25wt% EDTA-pancreatin, collecting cell suspension, centrifuging at 800rpm for 6min, discarding supernatant, leaving cell sediment, re-suspending the cell sediment by serum-free suspension medium (BSL-01 culture medium, guangzhou Baisai biological medicine technology Co., ltd.) and adjusting the cell density to 1.0X10 6 cells/mL, wherein the culture condition is 37 ℃ and 5% CO 2 and 120r/min shaking culture. Cell morphology was observed by sampling every 24 hours and counted. After 3 days of culture, the cells are subjected to centrifugal liquid exchange and passage until the cell number of each cell is more than or equal to 6.0X10 6 cells/mL, and the cells are stably and continuously cultured and passage is carried out for 30 generations, so that serum-free full-suspension culture type duck eye cornea epithelial cells, namely duck eye cornea epithelial cell suspension cell strains, are obtained.
And freezing and storing cells and establishing a cell bank every 5 passages in the construction process of the duck eye cornea epithelial cell suspension cell strain.
The serum-free total suspension culture type duck eye cornea epithelial cells are named as DCE-S of the duck eye cornea epithelial cells, and are preserved in China center for type culture collection (CCTCC NO: C2024189) which is located at university of Wuhan, wuhan and 2024 in 6-28 days when being passaged to 25 th generation. FIG. 2 shows the results of growth state of the DCE-S generation 25 of the sheldrake eye corneal epithelial suspension cells. FIG. 3 shows the stable passaging conditions of different generations of DCE-S (F9-F30) cells, wherein the cell density of DCE-SD cells is stabilized above 6.0X106 cells/mL when the generation number of DCE-S cells is F1, F9-F30.
Example 2 test of DCE-S inoculation of sheldrake eye corneal epithelial suspension cells with H9 subtype avian influenza Virus
Taking DCE-S generation 25 cells of the sheldrake eye cornea epithelial suspension cells, placing the cells in a shaking table for culturing for 72 hours at 37 ℃ with 5% CO 2 and 120r/min, diluting the cells to 4X 10 6 cells/mL by adding fresh culture medium, inoculating H9 subtype avian influenza virus (virus titer HA=9 log 2,EID50＝10-8.0/0.1 mL) at the same time according to 1%v/v, adding TPCK pancreatin with the final concentration of 5ug/mL, adjusting the temperature to 35 ℃, culturing for 72 hours, harvesting virus liquid, and detecting HA. The result shows that DCE-S of the sheldrake eye cornea epithelial suspension cells is sensitive to H9 subtype avian influenza virus, and HA is more than or equal to 9log 2. FIG. 4 is a cytopathic chart of the DCE-S inoculation of the sheldrake eye corneal epithelial suspension cells with H9 subtype avian influenza virus for 72H, massive cell death and cell lysis, more cell debris and obvious reduction of living cells.
Such strains are disclosed in Qi,Xuefeng et al."Down-regulation of cellular protein heme oxygenase-1inhibits proliferation of avian influenza virus H9N2 in chicken oviduct epithelial cells."The Journal of general virology vol.99,1(2018):36-43.doi:10.1099/jgv.0.000986.
Example 3 Duck eye corneal epithelial suspension cell DCE-S inoculated Duck circovirus (DuCV) test
Taking DCE-S generation 25 cells of the sheldrake eye cornea epithelial suspension cells, placing the cells in a shaking table for culturing for 72 hours at 37 ℃ with 5% CO 2 and 120r/min, adding fresh culture medium to dilute the cells to 4X 10 6 cells/mL when the cell density reaches above 6X 10 6 cells/mL, inoculating duck circovirus (virus titer TCID 50＝10-6.0/0.1 mL) at 5%v/v, adjusting the temperature to 37 ℃, harvesting virus liquid after culturing for 60 hours, and detecting TCID 50. The results show that DCE-S of the sheldrake eye corneal epithelium suspension cells is sensitive to duck circovirus, and TCID 50≥10-7.0/0.1 mL. FIG. 5 is a cytopathic chart of DCE-S of the sheldrake eye corneal epithelium suspension cells inoculated with duck circovirus for 60h, with a large number of cells dying and lysing, more cell debris and significantly reduced living cells.
The strain is disclosed in New Yong and the like, duck hepatitis A virus type 3 and duck circovirus double fluorescence quantitative PCR detection methods [ J ]. Chinese fowl literature.
Example 4 Duck eye corneal epithelial suspension cell DCE-S inoculated Duck tembusu Virus (DTMUV) test
Taking DCE-S generation 25 cells of the sheldrake eye cornea epithelial suspension cells, placing the cells in a shaking table for culturing for 72 hours at 37 ℃ with 5% CO 2 and 120r/min, adding fresh culture medium to dilute the cells to 4X 10 6 cells/mL when the cell density reaches above 6X 10 6 cells/mL, inoculating duck tembusu virus (virus titer TCID 50＝10-7.0/0.1 mL) at 0.5%v/v, adjusting the temperature to 37 ℃, culturing for 50 hours, and then harvesting virus liquid, and detecting TCID 50. The results show that the duck eye cornea epithelial cell suspension cell strain is sensitive to duck tembusu virus, and TCID 50≥10-7.5/0.1 mL. FIG. 6 is a cytopathic chart of duck eye cornea epithelial suspension cells DCE-S inoculated with duck Tembusu virus for 50h, cells dying and lysing in large quantity, cell fragments are more, and living cells are obviously reduced.
The establishment and preliminary application of one-step RT-PCR detection method of duck tembusu virus are disclosed in 2015 (volume 40), 5 th stage and 37-40 literature.
Claims (3)
1. A duck eye cornea epithelial cell line, named DCE-S, is preserved in China center for type culture collection (CCTCC NO: C2024189) at university of Wuhan, 2024, and 28 days.
2. The use of the duck eye cornea epithelial cell line of claim 1 in any one of 1) to 4):
1) Culturing the virus;
2) Preparing a product for culturing viruses;
3) Isolating the virus;
4) Preparing a virus-isolated product;
The virus includes at least one of avian influenza virus, duck circovirus, and duck tembusu virus.
3. A method of culturing a virus by inoculating the virus into the duck eye cornea epithelial cell line of claim 1, and culturing;
The virus includes at least one of avian influenza virus, duck circovirus, and duck tembusu virus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411276253.1A CN118956732B (en) | 2024-09-12 | 2024-09-12 | Duck eye cornea epithelial cell suspension cell strain, construction method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411276253.1A CN118956732B (en) | 2024-09-12 | 2024-09-12 | Duck eye cornea epithelial cell suspension cell strain, construction method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN118956732A CN118956732A (en) | 2024-11-15 |
| CN118956732B true CN118956732B (en) | 2025-07-29 |
Family
ID=93394676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411276253.1A Active CN118956732B (en) | 2024-09-12 | 2024-09-12 | Duck eye cornea epithelial cell suspension cell strain, construction method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118956732B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103725644A (en) * | 2013-02-06 | 2014-04-16 | 山东省滨州畜牧兽医研究院 | Cherry valley duck embryo epithelial cell line and establishment method thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3686276A1 (en) * | 2019-01-28 | 2020-07-29 | Freie Universität Berlin | Production of viruses in continuously growing epithelial cell lines derived from chicken gut |
| CN112294952A (en) * | 2019-08-02 | 2021-02-02 | 成都天邦生物制品有限公司 | Triple inactivated vaccine for newcastle disease, H9 subtype avian influenza and avian adenovirus |
| CN114107171B (en) * | 2021-11-12 | 2022-12-27 | 广东省华晟生物技术有限公司 | Goose retinal epithelial cell line and construction method and application thereof |
| CN114350601B (en) * | 2021-12-21 | 2022-12-27 | 广东省华晟生物技术有限公司 | Cherry valley duck fibroblast line and construction method and application thereof |
| CN114540292B (en) * | 2022-02-23 | 2024-06-28 | 苏州双洳生物科技有限公司 | Suspension domestication method and application of sheldrake embryo liver mesenchymal stem cells |
| CN116769712A (en) * | 2023-06-19 | 2023-09-19 | 济南磐升生物技术有限公司 | Method for domesticating corneal epithelial cells from serum culture to serum-free |
-
2024
- 2024-09-12 CN CN202411276253.1A patent/CN118956732B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103725644A (en) * | 2013-02-06 | 2014-04-16 | 山东省滨州畜牧兽医研究院 | Cherry valley duck embryo epithelial cell line and establishment method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN118956732A (en) | 2024-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114350601B (en) | Cherry valley duck fibroblast line and construction method and application thereof | |
| CN107460156B (en) | Serum-free full-suspension MDCK cell strain and application thereof in production of influenza virus | |
| CN113025574B (en) | A largemouth bass brain cell line and its application | |
| CN114317405B (en) | Serum-free full-suspension culture type F81 cell line and construction method and application thereof | |
| CN110093307A (en) | The method for adapting to the BHK-21-SC cell strain of serum free suspension culture and preparing vaccine antigen with the cell strain | |
| CN113249308B (en) | Perch arteriosus cell line and its application and culture method | |
| CN112410290A (en) | Micropterus salmoides cardiac fibroblast line and application thereof | |
| CN110551689B (en) | Channa argus brain cell line and construction method and application thereof | |
| CN114107171B (en) | Goose retinal epithelial cell line and construction method and application thereof | |
| CN104152403B (en) | A kind of method that establishing goose embryonic epithelium cell line and the goose embryonic epithelium cell line of foundation | |
| CN104974977B (en) | A kind of epinephelus lanceolatus fish nephridial tissue cell line and its construction method | |
| CN105483078A (en) | Isolation and primary culture methods of chicken small intestinal epithelial cells | |
| CN114717178A (en) | Isolated culture method and application of tree shrew testicular interstitial cells | |
| CN118956732B (en) | Duck eye cornea epithelial cell suspension cell strain, construction method and application thereof | |
| CN110295137B (en) | Channa argus kidney cell line and construction method and application thereof | |
| CN116836912B (en) | Lateolabrax japonicus kistrodon cell line and construction method and application thereof | |
| CN117431204A (en) | Method for culturing goat pox virus by goat kidney suspension cells | |
| CN113957037B (en) | Perch gill cell line, construction and application method thereof | |
| CN115948334B (en) | Mandarin fish brain cell clone cell strain and application thereof | |
| CN103725644B (en) | Cherry valley duck embryo epithelial cell line and method for building up thereof | |
| CN109679925A (en) | The preparation method and products thereof of duck tembusu virus liquid | |
| CN105420198B (en) | Application of Chicken Hepatoma Cell Line as Duck Plague Virus Host | |
| CN103320393A (en) | Method for culturing gosling plague virus by use of goose embryo continuous cell line and bioreactor | |
| CN118956738B (en) | Sheldrake embryo fibroblast line and construction method and application thereof | |
| CN118995585B (en) | Duck myocardial cell line and construction method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |